Evidence map›Paper›PMID 28484962›Full record

ArticleThe AAPS journal2017

Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells.

Emily A Gosselin, Lisa H Tostanoski, Christopher M Jewell

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Engineering metabolism to modulate immunity.Advanced drug delivery reviews · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Engineering Immune Tolerance with Biomaterials.Advanced healthcare materials · 2019
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Emily A GosselinFischell Department of Bioengineering, University of Maryland, 2212 Jeong H. Kim Engineering Building, 8228 Paint Branch Drive, College Park, Maryland, 20742, USA.
Lisa H TostanoskiFischell Department of Bioengineering, University of Maryland, 2212 Jeong H. Kim Engineering Building, 8228 Paint Branch Drive, College Park, Maryland, 20742, USA.
Christopher M JewellFischell Department of Bioengineering, University of Maryland, 2212 Jeong H. Kim Engineering Building, 8228 Paint Branch Drive, College Park, Maryland, 20742, USA. cmjewell@umd.edu.ORCID 0000-0002-6668-6928
University of Maryland, College Park · USUniversity of Mary · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune disease occurs when the immune system incorrectly targets the body's own tissue. Inflammatory CD4

Indexed as

AnimalsCD4-Positive T-LymphocytesCoculture TechniquesEnzyme-Linked Immunosorbent AssayFemaleImmunosuppressive AgentsInflammationMiceMice, Inbred C57BLTOR Serine-Threonine KinasesImmunosuppressive AgentsMTOR protein, humanTOR Serine-Threonine Kinasescontrolled releaseimmune tolerance and autoimmunitymicroparticle and nanoparticlerapamycin, everolimus, and temsirolimusvaccine and immunotherapy

Identifiers

PMID28484962
OpenAlexW2612251000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.